Last news
Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

...

CGTN: Why is people-centered development crucial to China?

CGTN: Why is people-centered development crucial to China?

...

Netac Unveils New Super-Fast Slim SSD for Improved Gaming and Performance

Netac Unveils New Super-Fast Slim SSD for Improved Gaming and Performance

...

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

...

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

...

AGBA Group (NASDAQ: 'AGBA') Comments on its Share Price Performance Since Listing in November 2022

AGBA Group (NASDAQ: 'AGBA') Comments on its Share Price Performance Since Listing in November 2022

...

GigaMedia Announces Amendment to One Exhibit in Notice of Annual General Meeting of Shareholders and Proxy Statement Previously Announced on May 19, 2023

GigaMedia Announces Amendment to One Exhibit in Notice of Annual General Meeting of Shareholders and Proxy Statement Previously Announced on May 19, 2023

...

ZW3D 2024: Unify Design, Simulation and Manufacturing to Improve Productivity

ZW3D 2024: Unify Design, Simulation and Manufacturing to Improve Productivity

...

menu
menu